Want to see AU:GSS full AI Analyst Report?
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.43
Previous CloseN/A
Volume34.30K
Average Volume (3M)459.90K
Market Cap
AU$17.04M
Enterprise Value-AU$6.57
Total Cash (Recent Filing)AU$22.09M
Total Debt (Recent Filing)AU$310.00K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Feb 16, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding227,138,820
10 Day Avg. Volume300,481
30 Day Avg. Volume459,900
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.43
Price to Sales (P/S)1.05
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$21.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic PlatformThe proprietary 3base® platform provides a foundation for differentiated multiplex molecular tests across gastrointestinal, respiratory, and other pathogen applications. A reusable technology platform can support product expansion and strengthen the company’s ability to serve multiple diagnostic workflows over time.
Recurring Consumables ModelConsumable assay sales can generate repeat purchasing as clinical laboratories perform ongoing infectious-disease testing. This usage-based model gives GSS a recurring revenue mechanism tied to customer test volumes, while associated software and workflow products may broaden the offering.
Very Low LeverageVery low debt reduces refinancing and solvency pressure and preserves financial flexibility relative to a highly leveraged business. Although losses remain significant, the conservative capital structure limits interest-related strain and leaves less dependence on lenders to sustain operations.
Bears Say
Falling Revenue And Severe LossesRevenue contraction combined with deeply negative gross and net margins indicates that recent operations are not covering product costs and the fixed-cost base. Continued losses weaken earnings quality, reduce reinvestment capacity, and make a durable return to profitability dependent on substantial operating improvement.
Persistent Cash BurnMulti-year negative operating and free cash flow shows that the business has not been self-funding its operations since 2022. Persistent cash burn can consume available resources, constrain investment in products and commercialization, and increase the importance of future funding or a cash-flow turnaround.
Shrinking Equity BaseThe sharp decline in equity reflects cumulative value erosion from sustained losses and weak capital productivity. Even with minimal debt, a shrinking capital base reduces the company’s financial buffer, limits resilience during continued underperformance, and can constrain its ability to fund growth internally.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.05 and its highest was AU$0.43 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$17.04M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Feb 16, 2027 which is in 144 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Aug 24, 2026. The company reported -AU$0.034 earnings per share for the quarter.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.034 in its last earnings report. Following the earnings report the stock price went up 9.589%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:GSS Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Australian Clinical Labs Ltd
―
Microba Life Sciences Limited
―